Marathon’s major misstep shows that drug pricing debate is here to stay
Pharmafocus | February 14, 2017
Marathon Pharmaceuticals’ approval, last week, by the FDA for its treatment for Duchenne muscular dystrophy would usually have been cause for celebration within the pharmaceutical company and more than likely it was – but only for the weekend. Starting on Monday morning, the price of the treatment started hitting the headlines and suddenly Marathon was experiencing a hangover to the party rather than sooner than they would have hoped.